文献速递心律失常心力衰竭与心肌病

房颤合并心衰患者的早期节律控制治疗:EAST-AFNET4预设亚组分析

Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure.
PubMed 文献 · Circulation · 2021-07-30

该研究为EAST-AFNET4随机试验的预设亚组分析,纳入798例合并心衰的房颤患者,比较早期节律控制与常规治疗对主要结局的影响。中位随访5.1年,早期节律控制组主要复合终点(心血管死亡、卒中、心衰恶化或急性冠脉综合征住院)发生率显著低于常规治疗组(5.7 vs 7.9/100患者年,HR 0.74,P=0.03),且不受心衰类型影响;安全性终点无显著差异。

要点

  • 房颤合并心衰患者早期节律控制可降低心血管死亡、卒中及心衰恶化住院复合终点。
  • 获益不受心衰类型(射血分数保留、中间值或降低)影响,交互作用P=0.63。
  • 主要安全性终点(死亡、卒中或节律控制相关严重不良事件)两组无显著差异。

核心结论

  • 在房颤诊断1年内启动节律控制治疗,对伴有心衰症状或体征的患者具有临床获益。

研究设计与样本

  • EAST-AFNET4随机试验的预设亚组分析,纳入798例合并心衰的房颤患者,随机接受早期节律控制或常规治疗。

主要发现

  • 2年时左室射血分数改善两组相似(早期节律控制组5.3±11.6%,常规治疗组4.9±11.6%,P=0.43)。
  • 早期节律控制还改善了死亡或心衰恶化住院的复合结局。

临床怎么用

  • 对于房颤合并心衰(NYHA II-III级或LVEF<50%)患者,可考虑在诊断1年内启动早期节律控制治疗以改善预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Even on optimal therapy, many patients with heart failure and atrial fibrillation experience cardiovascular complications. Additional treatments are needed to reduce these events, especially in patients with heart failure and preserved left ventricular ejection fraction. METHODS: This prespecified subanalysis of the randomized EAST-AFNET4 trial (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial) assessed the effect of systematic, early rhythm control therapy (ERC; using antiarrhythmic drugs or catheter ablation) compared with usual care (allowing rhythm control therapy to improve symptoms) on the 2 primary outcomes of the trial and on selected secondary outcomes in patients with heart failure, defined as heart failure symptoms New York Heart Association II to III or left ventricular ejection fraction [LVEF] <50%. RESULTS: This analysis included 798 patients (300 [37.6%] female, median age 71.0 [64.0, 76.0] years, 785 with known LVEF). The majority of patients (n=442) had heart failure and preserved LVEF (LVEF≥50%; mean LVEF 61±6.3%), the others had heart failure with midrange ejection fraction (n=211; LVEF 40%-49%; mean LVEF 44 ± 2.9%) or heart failure with reduced ejection fraction (n=132; LVEF<40%; mean LVEF 31±5.5%). Over the 5.1-year median follow-up, the composite primary outcome of cardiovascular death, stroke, or hospitalization for worsening of heart failure or for acute coronary syndrome occurred less often in patients randomly assigned to ERC (94/396; 5.7 per 100 patient-years) compared with patients randomly assigned to usual care (130/402; 7.9 per 100 patient-years; hazard ratio, 0.74 [0.56-0.97]; P=0.03), not altered by heart failure status (interaction P value=0.63). The primary safety outcome (death, stroke, or serious adverse events related to rhythm control therapy) occurred in 71 of 396 (17.9%) patients with heart failure randomly assigned to ERC and in 87 of 402 (21.6%) patients with heart failure randomly assigned to usual care (hazard ratio, 0.85 [0.62-1.17]; P=0.33). LVEF improved in both groups (LVEF change at 2 years: ERC 5.3±11.6%, usual care 4.9±11.6%, P=0.43). ERC also improved the composite outcome of death or hospitalization for worsening of heart failure. CONCLUSIONS: Rhythm control therapy conveys clinical benefit when initiated within 1 year of diagnosing atrial fibrillation in patients with signs or symptoms of heart failure. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01288352. URL: http://www.controlled-trials.com; Unique identifier: ISRCTN04708680. URL: https://www.clinicaltrialsregister.eu; Unique identifier: 2010-021258-20.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Rillig A, Magnussen C, Ozga AK, et al. Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure. Circulation. 2021. PMID: 34328366. doi:10.1161/CIRCULATIONAHA.121.056323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。